托里帕利马布加双重化疗作为初始不可切割的NSCLC的外科治疗:一个开放标签的第二阶段试验
Liang Zeng1, Huan Yan1, Wenjuan Jiang1
1Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Med (New York, N.Y.)
|February 1, 2025
概括
在72.5%的患者中,托里帕利马布加化疗将不可切除的非小细胞肺癌 (NSCLC) 转化为可切除的. 这种诱导疗法显示了100%的R0切除率和先进NSCLC的有希望的生存结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 术后托利帕利马布和化疗在可切除的非小细胞肺癌 (NSCLC) 中显示出有效性.
- 关于使用这种疗法将不可切除的NSCLC转化为可切除的数据有限.
研究的目的:
- 评估托利帕利马布加化学疗法的疗效和安全性,用于将最初不可切除的NSCLC转化为可切除的NSCLC.
- 评估诱导治疗后的R0切除率和其他临床结果.
主要方法:
- 40名未经治疗的患者患有不可切除的IIIA-IIIB阶段NSCLC,接受了托利帕利马布和化疗 2-4 个周期.
- 根据诱导治疗反应进行了手术切除.
- 主要终点是R0切除率;次要终点包括安全性,生存率和反应率.
主要成果:
- 40名患者中有29名 (72.5%) 接受了手术,实现了100%的R0切除率.
- 在58.6%的切除患者中观察到主要病理反应 (MPR),34.5%的病理完整反应 (pCR).
- 没有达到无事件和总生存的中位数;基线三级淋巴体结构 (TLS) 状态与pCR相关.
结论:
- 基于托里帕利马布的诱导疗法有效地将不可切除的NSCLC转化为可切除的NSCLC.
- 该方案提供了高的R0切除率,MPR率和有利的安全性.
- 鼓励生存结果和潜在的预测生物标志物 (TLS) 需要进一步调查.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
12:34Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
Published on: January 3, 2020
16.6K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...